Castro, M., Wenzel, S. E., Bleecker, E. R., Pizzichini, E., Kuna, P., Busse, W. W., . . . Raible, D. G. (2014). Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: A phase 2b randomised dose-ranging study. The Lancet Respiratory Medicine, 2(11), 879-890. https://doi.org/10.1016/S2213-2600(14)70201-2

Castro, Mario, et al. "Benralizumab, an Anti-interleukin 5 Receptor α Monoclonal Antibody, Versus Placebo for Uncontrolled Eosinophilic Asthma: A Phase 2b Randomised Dose-ranging Study." The Lancet Respiratory Medicine 2, no. 11 (2014): 879-890. https://doi.org/10.1016/S2213-2600(14)70201-2.

Castro, Mario, et al. "Benralizumab, an Anti-interleukin 5 Receptor α Monoclonal Antibody, Versus Placebo for Uncontrolled Eosinophilic Asthma: A Phase 2b Randomised Dose-ranging Study." The Lancet Respiratory Medicine, vol. 2, no. 11, 2014, pp. 879-890, https://doi.org/10.1016/S2213-2600(14)70201-2.